Business context and reporting period
Laboratory Corporation of America Holdings (Labcorp) filed this unaudited Form 10-Q for the quarter ended March 31, 2024. Its two segments are Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS); Fortrea’s former clinical development business is presented as discontinued operations. Dx and BLS accounted for approximately 78% and 22% of revenue, respectively.
Key financial metrics
Amounts are in millions of dollars except per-share data.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $3,176.6 | $3,037.8 |
| Gross profit / margin | $897.3 / 28.2% | $850.1 / 28.0% |
| Operating income / margin | $321.3 / 10.1% | $329.8 / 10.9% |
| Net earnings attributable to Labcorp | $228.0 | $212.9 |
| Diluted EPS | $2.69 | $2.39 |
| Operating cash flow, continuing operations | $(29.8) | $185.7 |
| Capital expenditures | $133.8 | $78.2 |
Cash and cash equivalents were $99.3 at March 31, 2024, compared with $536.8 at year-end 2023. Total debt was approximately $5.09 billion, comprising $2.04 billion classified as short-term and $3.05 billion long-term. The company had $957.6 of available revolving-credit capacity; $42.4 was drawn. It reported compliance with debt covenants and expects to remain compliant over the next 12 months.
Changes versus the prior comparable period
- Revenue rose 4.6%, reflecting 2.3% organic growth, 1.8% from acquisitions net of divestitures, and 0.5% favorable currency effects. Organic base-business growth of 4.2% was partly offset by a 1.9% decline in COVID-19 testing.
- Dx revenue increased 4.1% to $2,479.7; segment operating income fell 5.3% to $417.9 and margin declined to 16.9% from 18.5%. Management cited lower COVID-19 testing, adverse weather, and mix effects.
- BLS revenue increased 7.5% to $710.9; segment operating income rose 35.7% to $99.9 and margin improved to 14.1% from 11.1%, supported by organic growth and LaunchPad savings.
- Operating income declined 2.6%, although attributable net earnings and diluted EPS increased. SG&A rose 11.2% to $508.4, increasing from 15.1% to 16.0% of revenue.
- Continuing operating cash flow declined by $215.5 year over year to an outflow of $29.8, primarily due to lower cash earnings and working-capital timing, including higher receivables and lower accounts payable and accrued expenses.
Outlook, risks, contingencies, and unusual items
- Management said it expects to refinance $2.0 billion of debt coming due in the next 12 months. The company stated its cash, borrowing capacity, and operating cash generation should meet cash requirements, dividends, and share repurchases.
- Labcorp remains on track to deliver approximately $350 million of net savings from its three-year LaunchPad initiative by the end of 2024, including approximately $100 million to $125 million in fiscal 2024. No full-year revenue or earnings guidance is stated in the supplied filing text.
- Q1 acquisitions included Baystate Medical Center, Providence Medical Foundation, and Westpac Labs, with $259.2 cash paid. Separately, on April 24, Labcorp announced it was the winning bidder for select Invitae assets for $239 million; closing was anticipated in Q3 2024, subject to court approval and customary conditions.
- Other, net included $22.4 of transition-service fees charged to Fortrea and a $4.9 gain on the sale of Beacon Laboratory Benefit Solutions. Q1 also included a $2.5 impairment charge for a decommissioned robotic asset and $5.0 of restructuring and other charges.
- Material legal matters include the Ravgen patent case, where a jury awarded $272 million and the court added $100 million in enhanced damages; Labcorp disputes the verdict and is pursuing appeals. The company also disclosed multiple healthcare billing, privacy, employment, and other proceedings; it said it cannot estimate reasonably probable losses for certain matters.
- The FDA issued a final rule on laboratory-developed tests on April 29, 2024, after quarter-end, providing for a phased end to general enforcement discretion over four years, subject to exceptions. Labcorp is evaluating the rule; legal challenges may affect its implementation, and the ultimate business impact is uncertain.
- Foreign-currency translation adjustments reduced comprehensive earnings by $126.1 in Q1. Management also cited risks including reimbursement and regulatory changes, customer volumes and collections, competition, acquisitions, cybersecurity, and litigation.
- On April 25, the company announced an intended holding-company reorganization for May 17, 2024. The new parent was to be named Labcorp Holdings Inc.; shares were expected to continue trading on the NYSE under LH on a one-for-one basis.
Important facts for investors to verify
- Whether working-capital pressures reverse and operating cash flow recovers in subsequent quarters.
- Refinancing terms and timing for the $2.0 billion due within 12 months, alongside cash levels and revolving-credit availability.
- Progress against 2024 LaunchPad savings targets and whether Dx margins recover from Q1’s decline.
- Final approval, closing conditions, and integration implications for the Invitae asset purchase.
- Developments in the Ravgen appeal and other litigation, plus the financial impact of the FDA’s LDT rule.